Savara Inc. (SVRA) |
| 5.84 0.2 (3.55%) 02-25 16:00 |
| Open: | 5.76 |
| High: | 5.955 |
| Low: | 5.61 |
| Volume: | 1,064,239 |
| Market Cap: | 1,188(M) |
| PE Ratio: | -11.02 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 7.58 |
| Resistance 1: | 6.49 |
| Pivot price: | 5.52 |
| Support 1: | 5.63 |
| Support 2: | 5.09 |
| 52w High: | 7.005 |
| 52w Low: | 1.89 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Financials
| EPS | -0.530 |
| Book Value | 0.440 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.412 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -39.7 |
| Return on Equity (ttm) | -78.7 |
Company news
Wed, 25 Feb 2026
SVRA: Molbreevi advances toward FDA approval for aPAP, targeting a rare disease market with no current therapies - TradingView
Wed, 25 Feb 2026
SVRA: FDA priority review for MOLBREEVI targets 5,500 US APAP patients, launch prep underway - TradingView
Sat, 21 Feb 2026
Savara, Inc. (SVRA) Stock Analysis: Biotech Player With An 89% Upside Potential - DirectorsTalk Interviews
Sat, 21 Feb 2026
Savara (SVRA) Gains Priority Review for Molbreevi by FDA - GuruFocus
Fri, 20 Feb 2026
FDA Grants Priority Review to Savara's (SVRA) Molbreevi BLA - GuruFocus
Fri, 20 Feb 2026
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
